keyword
https://read.qxmd.com/read/38532742/previous-sars-cov-2-infections-and-their-impact-on-the-protection-from-reinfection-during-the-omicron-ba-5-wave-a-nested-case-control-study-among-vaccinated-adults-in-sweden
#1
JOURNAL ARTICLE
Fredrik Kahn, Carl Bonander, Mahnaz Moghaddassi, Claus Bohn Christiansen, Louise Bennet, Ulf Malmqvist, Malin Inghammar, Jonas Björk
OBJECTIVES: We evaluated the protection afforded by SARS-CoV-2 infection-induced immunity against reinfection among working-age vaccinated individuals during a calendar period from June to December 2022 when Omicron BA.5 was the dominating subvariant in Scania County, Sweden. METHODS: The study cohort (n = 71,592) mainly consisted of health care workers. We analyzed 4144 infected cases during the Omicron BA.5 dominance and 41,440 sex- and age-matched controls with conditional logistic regression...
March 2024: IJID Reg
https://read.qxmd.com/read/38528572/characteristics-of-traumatic-major-haemorrhage-in-a-tertiary-trauma-center
#2
JOURNAL ARTICLE
Pieter van Wyk, Marcus Wannberg, Anna Gustafsson, Jane Yan, Agneta Wikman, Louis Riddez, Carl-Magnus Wahlgren
BACKGROUND: Major traumatic haemorrhage is potentially preventable with rapid haemorrhage control and improved resuscitation techniques. Although advances in prehospital trauma management, haemorrhage is still associated with high mortality. The aim of this study was to use a recent pragmatic transfusion-based definition of major bleeding to characterize patients at risk of major bleeding and associated outcomes in this cohort after trauma. METHODS: This was a retrospective cohort study including all trauma patients (n = 7020) admitted to a tertiary trauma center from January 2015 to June 2020...
March 25, 2024: Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine
https://read.qxmd.com/read/38518789/interim-safety-and-immunogenicity-of-covid-19-omicron-ba-1-variant-containing-vaccine-in-children-in-the-usa-an-open-label-non-randomised-phase-3-trial
#3
JOURNAL ARTICLE
Avika Dixit, Richard Bennett, Kashif Ali, Carl Griffin, Robert A Clifford, Mark Turner, Rosanne Poston, Kelly Hautzinger, Anne Yeakey, Bethany Girard, Wen Zhou, Weiping Deng, Honghong Zhou, Sabine Schnyder Ghamloush, Barbara J Kuter, Karen Slobod, Jacqueline M Miller, Frances Priddy, Rituparna Das
BACKGROUND: Variant-containing mRNA vaccines for COVID-19 to broaden protection against SARS-CoV-2 variants are recommended based on findings in adults. We report interim safety and immunogenicity of an omicron BA.1 variant-containing (mRNA-1273.214) primary vaccination series and booster dose in paediatric populations. METHODS: This open-label, two-part, non-randomised phase 3 trial enrolled participants aged 6 months to 5 years at 24 US study sites. Eligible participants were generally healthy or had stable chronic conditions, without known SARS-CoV-2 infection in the previous 90 days...
March 19, 2024: Lancet Infectious Diseases
https://read.qxmd.com/read/38518189/the-effect-of-preoperative-chlorhexidine-gluconate-cleanse-on-lower-extremity-surgical-site-infections-a-retrospective-cohort-study
#4
JOURNAL ARTICLE
Michael P Dempsey, Alexandria M Riopelle, Margaret West, Aaditya Kumar, Carl F Schanbacher
BACKGROUND: Lower extremity surgical sites are at an increased risk of wound infection following Mohs micrographic surgery. OBJECTIVE: To evaluate the rate of lower extremity surgical site infections following a 14-day regimen of preoperative 4% chlorhexidine gluconate (CHG) rinses and postoperative wound occlusion for 14 days. MATERIALS AND METHODS: Retrospective data were collected from procedures performed by the senior author from January 2022 through June 2023...
March 22, 2024: Dermatologic Surgery: Official Publication for American Society for Dermatologic Surgery [et Al.]
https://read.qxmd.com/read/38513098/il7-increases-targeted-lipid-nanoparticle-mediated-mrna-expression-in-t-cells-in-vitro-and-in-vivo-by-enhancing-t-cell-protein-translation
#5
JOURNAL ARTICLE
Caitlin M Tilsed, Barzan A Sadiq, Tyler E Papp, Phurin Areesawangkit, Kenji Kimura, Estela Noguera-Ortega, John Scholler, Nicholas Cerda, Haig Aghajanian, Adrian Bot, Barbara Mui, Ying Tam, Drew Weissman, Carl H June, Steven M Albelda, Hamideh Parhiz
The use of lipid nanoparticles (LNP) to encapsulate and deliver mRNA has become an important therapeutic advance. In addition to vaccines, LNP-mRNA can be used in many other applications. For example, targeting the LNP with anti-CD5 antibodies (CD5/tLNP) can allow for efficient delivery of mRNA payloads to T cells to express protein. As the percentage of protein expressing T cells induced by an intravenous injection of CD5/tLNP is relatively low (4-20%), our goal was to find ways to increase mRNA-induced translation efficiency...
March 26, 2024: Proceedings of the National Academy of Sciences of the United States of America
https://read.qxmd.com/read/38499294/general-practitioners-perspectives-on-diagnostic-tests-for-children-a-qualitative-interview-study
#6
JOURNAL ARTICLE
Elizabeth T Thomas, Margaret Glogowska, Gail Hayward, Peter Gill, Rafael Perera, Carl Heneghan
Background Most healthcare contacts for children in the UK occur in general practice. Diagnostic tests can be beneficial in narrowing differential diagnoses, however, there is substantial variation in the use of tests for children in general practice. Unwarranted variation in testing can lead to variation in quality of care and exacerbate health inequities. No prior study has tried to understand why variation in testing exists for children in general practice. Aim To explore GP perspectives on using diagnostic tests for children in primary care and the underlying drivers of variation...
March 18, 2024: British Journal of General Practice
https://read.qxmd.com/read/38491330/author-correction-small-molecule-mediated-control-of-the-anti-tumour-activity-and-off-tumour-toxicity-of-a-supramolecular-bispecific-t-cell-engager
#7
Ningqiang Gong, Xuexiang Han, Lulu Xue, Margaret M Billingsley, Xisha Huang, Rakan El-Mayta, Jingya Qin, Neil C Sheppard, Carl H June, Michael J Mitchell
No abstract text is available yet for this article.
March 15, 2024: Nature Biomedical Engineering
https://read.qxmd.com/read/38484211/family-recall-of-and-response-to-germline-pathologic-variants-found-on-paired-tumor-germline-sequencing-in-pediatric-oncology
#8
JOURNAL ARTICLE
Michelle F Jacobs, Joshua W Goldman, Sarah Austin, Erika S Koeppe, Andrea M Murad, Carl J Koschmann, Arul M Chinnaiyan, Rajen J Mody
PURPOSE: Paired tumor-germline sequencing can identify somatic variants for targeted therapy and germline pathogenic variants (GPVs) causative of hereditary cancer/tumor predisposition syndromes. It is unknown how patients/families in pediatric oncology use information about an identified GPV. We assessed recall of germline results and actions taken on the basis of findings. METHODS: We completed phone surveys with patients (and/or their parent) with GPVs identified via a single academic medical center's paired tumor-germline sequencing study...
March 2024: JCO Precision Oncology
https://read.qxmd.com/read/38483486/implementing-patient-reported-outcome-measures-on-an-adolescent-inpatient-psychiatry-unit-a-feasibility-study
#9
JOURNAL ARTICLE
Carl Waitz, Annmarie Caracansi, Katy Kaufman, Emily Campbell, Ethan Anglemyer, Yohanis Anglero-Diaz, Sherry Paden, Billy Zou, Patricia Ibeziako
This article examines the feasibility of implementing patient-reported outcome (PRO) measures with adolescents on an inpatient psychiatry service. During the study period (March 8, 2021, to June 7, 2022), a total of 154 patient encounters were recorded for adolescents between 12 and 17 years of age. PROs were piloted during the first 3 months of the study period, with a focus on technical implementation. In the 12 months from June 8, 2021, through June 7, 2022, the PRO project moved to full implementation across all patient encounters...
March 14, 2024: Psychological Services
https://read.qxmd.com/read/38480922/intrathecal-bivalent-car-t-cells-targeting-egfr-and-il13r%C3%AE-2-in-recurrent-glioblastoma-phase-1-trial-interim-results
#10
JOURNAL ARTICLE
Stephen J Bagley, Meghan Logun, Joseph A Fraietta, Xin Wang, Arati S Desai, Linda J Bagley, Ali Nabavizadeh, Danuta Jarocha, Rene Martins, Eileen Maloney, Lester Lledo, Carly Stein, Amy Marshall, Rachel Leskowitz, Julie K Jadlowsky, Shannon Christensen, Bike Su Oner, Gabriela Plesa, Andrea Brennan, Vanessa Gonzalez, Fang Chen, Yusha Sun, Whitney Gladney, David Barrett, MacLean P Nasrallah, Wei-Ting Hwang, Guo-Li Ming, Hongjun Song, Donald L Siegel, Carl H June, Elizabeth O Hexner, Zev A Binder, Donald M O'Rourke
Recurrent glioblastoma (rGBM) remains a major unmet medical need, with a median overall survival of less than 1 year. Here we report the first six patients with rGBM treated in a phase 1 trial of intrathecally delivered bivalent chimeric antigen receptor (CAR) T cells targeting epidermal growth factor receptor (EGFR) and interleukin-13 receptor alpha 2 (IL13Rα2). The study's primary endpoints were safety and determination of the maximum tolerated dose. Secondary endpoints reported in this interim analysis include the frequency of manufacturing failures and objective radiographic response (ORR) according to modified Response Assessment in Neuro-Oncology criteria...
March 13, 2024: Nature Medicine
https://read.qxmd.com/read/38460119/promoting-diverse-perspectives-addressing-health-disparities-related-to-alzheimer-s-and-all-dementias
#11
JOURNAL ARTICLE
Gladys Maestre, Carl Hill, Percy Griffin, Stephen Hall, William Hu, Jason Flatt, Ganesh Babulal, Roland Thorpe, J Neil Henderson, Dedra Buchwald, Spero Manson, Ethan Cicero, Andrea Gilmore-Bykovskyi, Alyssa Gamaldo, Crystal Glover, Lisa Barnes, Amy Kind, Bryan James, Adina Zeki Al Hazzouri, Whitney Wharton, Paulo Caramelli, Sarah Szanton, Rachel Whitmer, Jada Benn Torres, Kacie Deters, Ozioma Okonkwo, Rina Das, Karen Martinez-Gonzalez, Maria Carrillo
Dementia research lacks appropriate representation of diverse groups who often face substantial adversity and greater risk of dementia. Current research participants are primarily well-resourced, non-Hispanic White, cisgender adults who live close to academic medical centers where much of the research is based. Consequently, the field faces a knowledge gap about Alzheimer's-related risk factors in those other groups. The Alzheimer's Association hosted a virtual conference on June 14-16, 2021, supported in part by the National Institute on Aging (R13 AG072859-01), focused on health disparities...
March 9, 2024: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
https://read.qxmd.com/read/38419362/antigen-presenting-cell-mimetic-lipid-nanoparticles-for-rapid-mrna-car-t-cell-cancer-immunotherapy
#12
JOURNAL ARTICLE
Ann E Metzloff, Marshall S Padilla, Ningqiang Gong, Margaret M Billingsley, Xuexiang Han, Maria Merolle, David Mai, Christian G Figueroa-Espada, Ajay S Thatte, Rebecca M Haley, Alvin J Mukalel, Alex G Hamilton, Mohamad-Gabriel Alameh, Drew Weissman, Neil C Sheppard, Carl H June, Michael J Mitchell
CAR T cell therapy has achieved remarkable clinical success for the treatment of hematological malignancies. However, producing these bespoke cancer-killing cells is a complicated ex vivo process involving leukapheresis, artificial T cell activation, and CAR construct introduction. The activation step requires the engagement of CD3/TCR and CD28 and is vital for T cell transfection and differentiation. Though antigen presenting cells facilitate activation in vivo, ex vivo activation relies on antibodies against CD3 and CD28 conjugated to magnetic beads...
February 28, 2024: Advanced Materials
https://read.qxmd.com/read/38408246/enhancing-chimeric-antigen-receptor-t-cell-therapy-by-modulating-the-p53-signaling-network-with-%C3%AE-133p53%C3%AE
#13
JOURNAL ARTICLE
Christopher Roselle, Izumi Horikawa, Linhui Chen, Andre R Kelly, Donna Gonzales, Tong Da, Nils Wellhausen, Philipp C Rommel, Daniel Baker, Megan Suhoski, John Scholler, Roddy S O'Connor, Regina M Young, Curtis C Harris, Carl H June
Chimeric antigen receptor (CAR) T cell dysfunction is a major barrier to achieving lasting remission in hematologic cancers, especially in chronic lymphocytic leukemia (CLL). We have shown previously that Δ133p53α, an endogenous isoform of the human TP53 gene, decreases in expression with age in human T cells, and that reconstitution of Δ133p53α in poorly functional T cells can rescue proliferation [A. M. Mondal et al. , J. Clin. Invest. 123 , 5247-5257 (2013)]. Although Δ133p53α lacks a transactivation domain, it can form heterooligomers with full-length p53 and modulate the p53-mediated stress response [I...
March 5, 2024: Proceedings of the National Academy of Sciences of the United States of America
https://read.qxmd.com/read/38386999/reinfusion-of-cd19-car-t-cells-for-relapse-prevention-and-treatment-in-children-with-acute-lymphoblastic-leukemia
#14
JOURNAL ARTICLE
Regina M Myers, Kaitlin J Devine, Yimei Li, Sophie Lawrence, Allison Barz Leahy, Hongyan Liu, Lauren Vernau, Colleen Callahan, Diane Baniewicz, Stephan Kadauke, Regina McGuire, Gerald Wertheim, Irina Kulikovskaya, Vanessa Gonzalez, Joseph A Fraietta, Amanda DiNofia, Stephen P Hunger, Susan R Rheingold, Richard Aplenc, Carl H June, Stephan A Grupp, Lisa Wray, Shannon L Maude
Relapse after CD19-directed chimeric antigen receptor (CAR)-modified T-cells remains a substantial challenge. Short CAR T-cell persistence contributes to relapse risk, necessitating novel approaches to prolong durability. CAR T-cell reinfusion (CARTr) represents a potential strategy to reduce the risk of, or treat, relapsed disease after initial CAR infusion (CARTi). We conducted a retrospective review of reinfusion of murine (CTL019) or humanized (huCART19) anti-CD19.4-1BB CAR T-cells across 3 clinical trials or commercial tisagenlecleucel for relapse prevention [peripheral B-cell recovery (BCR) or bone marrow hematogones ≤6 months after CARTi], minimal residual disease (MRD) or relapse, or nonresponse to CARTi...
February 22, 2024: Blood Advances
https://read.qxmd.com/read/38386106/update-on-olfactory-neuroblastoma
#15
REVIEW
Fernando Lopez, Abbas Agaimy, Alessandro Franchi, Carlos Suárez, Vincent Vander Poorten, Antti A Mäkitie, Akihiro Homma, Avraham Eisbruch, Kerry D Olsen, Nabil F Saba, Sandra Nuyts, Carl Snyderman, Jonathan J Beitler, June Corry, Ehab Hanna, Henrik Hellquist, Alessandra Rinaldo, Alfio Ferlito
Olfactory neuroblastomas are uncommon malignancies that arise from olfactory receptor cells located high in the nasal cavity. Accurate diagnosis plays a crucial role in determining clinical results and guiding treatment decisions. Diagnosis can be a major challenge for pathologists, especially when dealing with tumours with poor differentiation. The discovery of several molecular and immunohistochemical markers would help to overcome classification difficulties. Due to the paucity of large-scale studies, standardisation of diagnosis, treatment and prediction of outcome remains a challenge...
February 22, 2024: Virchows Archiv: An International Journal of Pathology
https://read.qxmd.com/read/38382965/prevalence-of-occupational-moral-injury-and-post-traumatic-embitterment-disorder-a-systematic-review-and-meta-analysis
#16
JOURNAL ARTICLE
Chloe J Brennan, Carl Roberts, Jon C Cole
OBJECTIVES: Occupational moral injury and post-traumatic embitterment disorder (PTED) describe the psychological distress caused by exposure to injustice at work. This meta-analysis aims to determine the prevalence of occupational moral injury and PTED and establish whether prevalence estimates differ depending on occupation. DESIGN: A systematic review and meta-analysis. DATA SOURCES: Google Scholar, PubMed, APA PsycINFO, Web of Science Core Collection, Scopus, ScienceDirect and Sage Journals Online were searched in June 2020 and updated in November 2022...
February 20, 2024: BMJ Open
https://read.qxmd.com/read/38378820/small-molecule-mediated-control-of-the-anti-tumour-activity-and-off-tumour-toxicity-of-a-supramolecular-bispecific-t-cell-engager
#17
JOURNAL ARTICLE
Ningqiang Gong, Xuexiang Han, Lulu Xue, Margaret M Billingsley, Xisha Huang, Rakan El-Mayta, Jingya Qin, Neil C Sheppard, Carl H June, Michael J Mitchell
The broader clinical use of bispecific T cell engagers for inducing anti-tumour toxicity is hindered by their on-target off-tumour toxicity and the associated neurotoxicity and cytokine-release syndrome. Here we show that the off-tumour toxicity of a supramolecular bispecific T cell engager binding to the T cell co-receptor CD3 and to the human epidermal growth factor receptor 2 on breast tumour cells can be halted by disengaging the T cells from the tumour cells via the infusion of the small-molecule drug amantadine, which disassembles the supramolecular aggregate...
February 20, 2024: Nature Biomedical Engineering
https://read.qxmd.com/read/38356444/editor-s-note-in-vivo-persistence-tumor-localization-and-antitumor-activity-of-car-engineered-t-cells-is-enhanced-by-costimulatory-signaling-through-cd137-4-1bb
#18
De-Gang Song, Qunrui Ye, Carmine Carpenito, Mathilde Poussin, Li-Ping Wang, Chunyan Ji, Mariangela Figini, Carl H June, George Coukos, Daniel J Powell
No abstract text is available yet for this article.
February 15, 2024: Cancer Research
https://read.qxmd.com/read/38348286/the-dcm-project-portal-a-direct-to-participant-platform-of-the-dcm-research-project
#19
JOURNAL ARTICLE
Elizabeth S Jordan, Phoenix L Grover, Jay Lin, Carl A Starkey, Elizabeth A Finley, Hanyu Ni, Ray E Hershberger
STUDY OBJECTIVE: To develop a digital platform to conduct family-based, dilated cardiomyopathy (DCM) genetic research. DESIGN: The DCM Project Portal, a direct-to-participant electronic recruitment, consent, and communication tool, was designed using prior experience with traditional enrollment methods and characteristics and feedback of current participants. PARTICIPANTS: DCM patients (probands) and their family members enrolled from June 7, 2016 to March 15, 2020 at 25 US advanced heart failure programs...
February 2024: American heart journal plus: cardiology research and practice
https://read.qxmd.com/read/38326511/zfp36-disruption-is-insufficient-to-enhance-the-function-of-mesothelin-targeting-human-car-t-cells
#20
JOURNAL ARTICLE
David Mai, Tifara Boyce, Aakash Mehta, Jordan Reff, John Scholler, Neil C Sheppard, Carl H June
Loss of inflammatory effector function, such as cytokine production and proliferation, is a fundamental driver of failure in T cell therapies against solid tumors. Here, we used CRISPR/Cas9 to genetically disrupt ZFP36, an RNA binding protein that regulates the stability of mRNAs involved in T cell inflammatory function, such as the cytokines IL2 and IFNγ, in human T cells engineered with a clinical-stage mesothelin-targeting CAR to determine whether its disruption could enhance antitumor responses. ZFP36 disruption slightly increased antigen-independent activation and cytokine responses but did not enhance overall performance in vitro or in vivo in a xenograft tumor model with NSG mice...
February 7, 2024: Scientific Reports
keyword
keyword
72549
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.